Ancient herbs meet modern medicine in new fertility trial for women with low egg reserve

NCT ID NCT07296614

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial will test whether adding a traditional Chinese herbal formula to the standard fertility drug letrozole can improve natural pregnancy rates in women aged 22–39 with diminished ovarian reserve (low egg supply). The study plans to enroll 320 women who will receive either the combined treatment or a placebo plus letrozole. The main goal is to see if more women achieve a confirmed pregnancy within the study period.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Letrozole and Xiehe DOR Kidney-Tonifying Universal Formula (Chinese herbal granules)
What this could lead to
If successful, this combination therapy could offer a new, non-invasive option to help women with diminished ovarian reserve conceive naturally without IVF.
What could go wrong
This is a Phase 3 trial, but it has not yet started recruiting. The herbal formula is specific to Chinese medicine diagnosis, so results may not apply to all women. There is also a risk the placebo group performs similarly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIMINISHED OVARIAN RESERVE (DOR) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking union medical college hospital

    Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.